Literature DB >> 3299827

Pathophysiology of age-related macular degeneration.

R W Young.   

Abstract

The clinical and histopathological features of age-related macular degeneration (AMD) include a relationship with age, and the presence of pigmentary disturbances, drusen, thickening of Bruch's membrane, and basal laminar deposits. AMD is an advanced stage of a deteriorative process that takes place in all eyes. The primary lesion in AMD appears to reside in the retinal pigment epithelium (RPE), possibly resulting from its high rate of molecular degradation. Beginning early in life, and continuing throughout the life span, cells of the RPE gradually accumulate sacs of molecular debris. These residual bodies (lipofuscin) are remnants of the incomplete degradation of abnormal molecules which have been damaged within the RPE cells or derived from phagocytized rod and cone membranes. Progressive engorgement of RPE cells with these functionless residues is associated with the extrusion of aberrant materials which accumulate in Bruch's membrane and aggregate in the form of drusen and basal laminar deposits. These excretions contribute to the further deterioration of the RPE. Loss of vision results from death of visual cells due to degeneration of RPE cells, or the effects of leakage from neovascular membranes that invade the region of abnormal extracellular deposits.

Entities:  

Mesh:

Year:  1987        PMID: 3299827     DOI: 10.1016/0039-6257(87)90115-9

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  130 in total

1.  Dynamics of phosphorothioate oligonucleotides in normal and laser photocoagulated retina.

Authors:  W Y Shen; K L Garrett; L da Cruz; I J Constable; P E Rakoczy
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

2.  Electrophysiological changes after 360 degrees retinotomy and macular translocation for subfoveal choroidal neovascularisation in age related macular degeneration.

Authors:  C Lüke; S Aisenbrey; M Lüke; G Marzella; K U Bartz-Schmidt; P Walter
Journal:  Br J Ophthalmol       Date:  2001-08       Impact factor: 4.638

3.  Radiotherapy for isolated occult subfoveal neovascularisation in age related macular degeneration: a pilot study.

Authors:  G Donati; D Soubrane; M Quaranta; G Coscas; G Soubrane
Journal:  Br J Ophthalmol       Date:  1999-06       Impact factor: 4.638

Review 4.  Why study rod cell death in retinal degenerations and how?

Authors:  C E Remé; C Grimm; F Hafezi; H P Iseli; A Wenzel
Journal:  Doc Ophthalmol       Date:  2003-01       Impact factor: 2.379

5.  Macular pigment density in healthy subjects quantified with a modified confocal scanning laser ophthalmoscope.

Authors:  Henrike Wüstemeyer; Andreas Moessner; Cornelia Jahn; Sebastian Wolf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-07-17       Impact factor: 3.117

6.  Serum levels of antioxidants and age-related macular degeneration.

Authors:  N C Tsang; P L Penfold; P J Snitch; F Billson
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

7.  Fundus autofluorescence and the bisretinoids of retina.

Authors:  Janet R Sparrow; Yalin Wu; Takayuki Nagasaki; Kee Dong Yoon; Kazunori Yamamoto; Jilin Zhou
Journal:  Photochem Photobiol Sci       Date:  2010-09-23       Impact factor: 3.982

8.  The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study.

Authors:  G McGwin; T A Hall; A Xie; C Owsley
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

9.  Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells.

Authors:  Dongli Yang; Susan G Elner; Zong-Mei Bian; Gerd O Till; Howard R Petty; Victor M Elner
Journal:  Exp Eye Res       Date:  2007-06-27       Impact factor: 3.467

10.  Low glutathione reductase and peroxidase activity in age-related macular degeneration.

Authors:  S M Cohen; K L Olin; W J Feuer; L Hjelmeland; C L Keen; L S Morse
Journal:  Br J Ophthalmol       Date:  1994-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.